At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Jun 30, 2026 at 07:30 ET
Pyxis Oncology announced a $50M private placement (plus up to $64M from warrants) led by BVF Partners, extending cash runway into Q2 2027. The company also pushed back its Phase 1 monotherapy data readout for MICVO in HNSCC to Fall 2026 and combination data to Q4 2026. The financing is dilutive but provides capital to advance the lead ADC program through key milestones.
- Private placement of 19,600,153 shares at $2.551/share, raising $50M upfront
- Warrants for equal number of shares at $3.289/share, potentially adding $64M if exercised
- Cash runway extended into Q2 2027
- Phase 1 monotherapy data for MICVO in 2L+ R/M HNSCC delayed to Fall 2026 (previously earlier)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access